Zobrazeno 1 - 10
of 1 599
pro vyhledávání: '"Homologous recombination Deficiency"'
Autor:
Heidelinde Fiegl, Simon Schnaiter, Daniel U. Reimer, Katharina Leitner, Petra Nardelli, Irina Tsibulak, Verena Wieser, Katharina Wimmer, Esther Schamschula, Christian Marth, Alain G. Zeimet
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background In high-grade ovarian cancer (HGOC), determination of homologous recombination deficiency (HRD) status is commonly used in routine practice to predict response to platinum-based therapy or poly (ADP-ribose) polymerase inhibitors (
Externí odkaz:
https://doaj.org/article/0bdf725b0b91401bac844e6c5607a2b3
Autor:
Bonnita Werner, Elyse Powell, Jennifer Duggan, Marilisa Cortesi, Yeh Chen Lee, Vivek Arora, Ramanand Athavale, Michael Dean, Kristina Warton, Caroline E. Ford
Publikováno v:
Molecular Oncology, Vol 18, Iss 11, Pp 2668-2683 (2024)
The emergence of targeted therapies has transformed ovarian cancer treatment. However, biomarker profiling for precision medicine is limited by access to quality, tumour‐enriched tissue samples. The use of cell‐free DNA (cfDNA) in ascites present
Externí odkaz:
https://doaj.org/article/a862393c1ac74143b9221afef01ea9a5
Autor:
Chiara Maria Lavinia Loeffler, Omar S. M. El Nahhas, Hannah Sophie Muti, Zunamys I. Carrero, Tobias Seibel, Marko van Treeck, Didem Cifci, Marco Gustav, Kevin Bretz, Nadine T. Gaisa, Kjong-Van Lehmann, Alexandra Leary, Pier Selenica, Jorge S. Reis-Filho, Nadina Ortiz-Bruechle, Jakob Nikolas Kather
Publikováno v:
BMC Biology, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Homologous recombination deficiency (HRD) is recognized as a pan-cancer predictive biomarker that potentially indicates who could benefit from treatment with PARP inhibitors (PARPi). Despite its clinical significance, HRD testing
Externí odkaz:
https://doaj.org/article/003303862b20434e84941368c6c014a7
Autor:
Diwei Zhao, Anqi Wang, Yuanwei Li, Xinyang Cai, Junliang Zhao, Tianyou Zhang, Yi Zhao, Yu Dong, Fangjian Zhou, Yonghong Li, Jun Wang
Publikováno v:
Journal of the National Cancer Center, Vol 4, Iss 3, Pp 280-287 (2024)
Background: The homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitors (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score
Externí odkaz:
https://doaj.org/article/0fcf1b8a164e4a3ba8d847e617c3c753
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 7, Pp 561-566 (2024)
ObjectiveTo investigate the potential significance of FOXP3 expression in BRCA1/2-mutant breast cancer. MethodsA total of 48 BRCA mutation carriers (16 with BRCA1 and 32 with BRCA2) and 78 age-matched non-carriers were included in this study. Immunoh
Externí odkaz:
https://doaj.org/article/afc5471d38904448bc059fe915df2e14
Autor:
Jae Jun Lee, Hyun Ju Kang, Donghyo Kim, Si On Lim, Stephanie S. Kim, Gahyun Kim, Sanguk Kim, Jin-Ku Lee, Jinho Kim
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Homologous recombination deficiency (HRD) stands as a clinical indicator for discerning responsive outcomes to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors. One of the conventional approaches to HRD
Externí odkaz:
https://doaj.org/article/e274f62f8c0b4cfd914d0c83244325dd
Autor:
Alfonso Cortés, Elena López-Miranda, Adela Fernández-Ortega, Vicente Carañana, Sonia Servitja, Ander Urruticoechea, Laura Lema-Roso, Antonia Márquez, Alexandros Lazaris, Daniel Alcalá-López, Leonardo Mina, Petra Gener, Jose Rodríguez-Morató, Gabriele Antonarelli, Antonio Llombart-Cussac, José Pérez-García, Javier Cortés
Publikováno v:
Breast, Vol 78, Iss , Pp 103834- (2024)
Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multic
Externí odkaz:
https://doaj.org/article/b40824f923304c0d88d41f079397d8b6
Autor:
Yulu Wang, Bowen Ding, Yunlan Tao, Lingli Huang, Qian Zhu, Chengying Gao, Mingli Feng, Yuchen Han
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 6, Pp n/a-n/a (2024)
Abstract Homologous recombination deficiency (HRD) represents an impairment in the homologous recombination repair (HRR) pathway, crucial for repairing DNA double‐strand breaks and contributing to genomic instability in cancer. The HRD score may be
Externí odkaz:
https://doaj.org/article/722692d795e941e2b73dcabf7a4794d3
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDespite advances in neuro-oncology, treatments of glioma and tools for predicting the outcome of patients remain limited. The objective of this research is to construct a prognostic model for glioma using the Homologous Recombination Defici
Externí odkaz:
https://doaj.org/article/3e8a75163c38425e976b85aa611ed752
Publikováno v:
Успехи молекулярной онкологии, Vol 11, Iss 2, Pp 116-129 (2024)
Introduction. It has been established that the presence of homologous recombination deficiency in a breast tumor is associated with the effectiveness of treatment. But despite the high chemosensitivity of the tumor to DNA-damaging agents, complete pa
Externí odkaz:
https://doaj.org/article/f002c3a047694a818f480db8fa6bfe71